Skip to content

Released Nov 8, 2018, before the open

10-Q filed Nov 8, 2018, 39 days after period end · 0001144204-18-058118

Q3 2018 · 10-Q
Revenue$4.29M+61.1% vs Q3 2017+33.2% vs Q2 2018
Net Income-$21.54MN/M vs Q3 2017N/M vs Q2 2018
EPS Diluted-$0.87N/M vs Q3 2017N/M vs Q2 2018
Operating Income-$22,575,000N/M
Operating Cash Flowderived-$16,684,000N/M
Free Cash Flowderived-$16,721,000N/M
Margins · derived
Operating margin-526.7%−58.6 pt vs Q3 2017
Net margin-502.5%−41.0 pt vs Q3 2017

What the release said

The release

Same quarter

MetricQ3 2018Q3 2017Q3 2016Q3 2015
Revenue$4.29M$2.66M——
Net Income-$21.54M-$12.27M-$11.57M-$6.62M
EPS Diluted-$0.87-$710.00-$0.67-$0.38

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR